Creative Planning Vertex Pharmaceuticals Inc Transaction History

Creative Planning

  • $101 Billion
  • Q3 2024

A detailed history of Creative Planning transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Creative Planning holds 80,467 shares of VRTX stock, worth $36.3 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
80,467
Previous 79,117 1.71%
Holding current value
$36.3 Million
Previous $37.1 Million 0.92%
% of portfolio
0.04%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024
BUY
$460.0 - $505.78 $621,000 - $682,803
1,350 Added 1.71%
80,467 $37.4 Million
Q2 2024

Aug 15, 2024
BUY
$392.81 - $485.53 $1.57 Million - $1.94 Million
3,998 Added 5.32%
79,117 $37.1 Million
Q1 2024

May 10, 2024
BUY
$407.69 - $446.08 $767,680 - $839,968
1,883 Added 2.57%
75,119 $31.4 Million
Q4 2023

Feb 14, 2024
SELL
$343.0 - $410.68 $16.6 Million - $19.8 Million
-48,292 Reduced 39.74%
73,236 $29.8 Million
Q3 2023

Nov 16, 2023
BUY
$338.18 - $362.46 $17.7 Million - $18.9 Million
52,243 Added 75.4%
121,528 $42.3 Million
Q2 2023

Jul 21, 2023
BUY
$314.42 - $351.91 $814,033 - $911,094
2,589 Added 3.88%
69,285 $24.4 Million
Q1 2023

May 15, 2023
BUY
$283.23 - $323.1 $350,072 - $399,351
1,236 Added 1.89%
66,696 $21 Million
Q4 2022

Feb 10, 2023
BUY
$285.76 - $321.48 $16.2 Million - $18.2 Million
56,673 Added 644.96%
65,460 $18.9 Million
Q3 2022

Nov 03, 2022
SELL
$273.83 - $305.53 $1.18 Million - $1.32 Million
-4,318 Reduced 32.95%
8,787 $2.54 Million
Q2 2022

Aug 15, 2022
BUY
$234.96 - $292.55 $1.71 Million - $2.13 Million
7,280 Added 124.98%
13,105 $3.69 Million
Q1 2022

May 16, 2022
SELL
$221.42 - $260.97 $151,229 - $178,242
-683 Reduced 10.49%
5,825 $1.52 Million
Q4 2021

Feb 11, 2022
SELL
$177.01 - $223.45 $5.76 Million - $7.27 Million
-32,516 Reduced 83.32%
6,508 $1.43 Million
Q3 2021

Nov 10, 2021
BUY
$181.39 - $202.99 $1.25 Million - $1.4 Million
6,914 Added 21.53%
39,024 $7.08 Million
Q2 2021

Aug 04, 2021
BUY
$187.49 - $221.1 $4.75 Million - $5.6 Million
25,348 Added 374.86%
32,110 $6.48 Million
Q1 2021

Apr 30, 2021
BUY
$207.02 - $241.31 $74,320 - $86,630
359 Added 5.61%
6,762 $1.45 Million
Q4 2020

Jan 29, 2021
SELL
$207.01 - $276.09 $6,003 - $8,006
-29 Reduced 0.45%
6,403 $1.51 Million
Q3 2020

Nov 05, 2020
BUY
$255.65 - $303.1 $630,944 - $748,050
2,468 Added 62.26%
6,432 $1.75 Million
Q2 2020

Jul 23, 2020
BUY
$225.48 - $295.8 $228,411 - $299,645
1,013 Added 34.33%
3,964 $1.15 Million
Q1 2020

May 05, 2020
SELL
$199.77 - $247.81 $112,670 - $139,764
-564 Reduced 16.05%
2,951 $702,000
Q4 2019

Jan 30, 2020
BUY
$166.71 - $223.91 $22,339 - $30,003
134 Added 3.96%
3,515 $769,000
Q3 2019

Nov 01, 2019
SELL
$166.23 - $187.09 $31,085 - $34,985
-187 Reduced 5.24%
3,381 $573,000
Q2 2019

Jul 26, 2019
SELL
$164.61 - $190.37 $69,630 - $80,526
-423 Reduced 10.6%
3,568 $654,000
Q1 2019

Apr 24, 2019
SELL
$163.73 - $194.7 $42,733 - $50,816
-261 Reduced 6.14%
3,991 $734,000
Q4 2018

Feb 01, 2019
BUY
$151.91 - $192.21 $38,433 - $48,629
253 Added 6.33%
4,252 $705,000
Q3 2018

Oct 25, 2018
BUY
$167.73 - $192.74 $82,355 - $94,635
491 Added 14.0%
3,999 $771,000
Q2 2018

Jul 20, 2018
SELL
$145.72 - $169.96 $19,235 - $22,434
-132 Reduced 3.63%
3,508 $596,000
Q1 2018

Apr 18, 2018
SELL
$151.6 - $177.13 $109,606 - $128,064
-723 Reduced 16.57%
3,640 $593,000
Q4 2017

Jan 17, 2018
BUY
$137.28 - $155.55 $70,424 - $79,797
513 Added 13.32%
4,363 $654,000
Q3 2017

Oct 17, 2017
BUY
$148.13 - $162.24 $570,300 - $624,624
3,850
3,850 $585,000

Others Institutions Holding VRTX

# of Institutions
1,723
Shares Held
222M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email